{"id":6755,"date":"2024-12-03T17:34:58","date_gmt":"2024-12-03T15:34:58","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/?p=6755"},"modified":"2026-02-19T17:36:20","modified_gmt":"2026-02-19T15:36:20","slug":"genethon-and-hansa-biopharma-launch-a-phase-2-clinical-trial-for-crigler-najjar-syndrome","status":"publish","type":"post","link":"https:\/\/www.institut-biotherapies.fr\/en\/2024\/12\/03\/genethon-and-hansa-biopharma-launch-a-phase-2-clinical-trial-for-crigler-najjar-syndrome\/","title":{"rendered":"Genethon and Hansa Biopharma launch a phase 2 clinical trial for Crigler-Najjar syndrome"},"content":{"rendered":"<div class=\"chapo\">\n<p>The trial will be conducted in patients for whom pre-existing anti-AAV antibodies are currently a limitation to gene therapy treatment.<\/p>\n<\/div>\n<div>\n<div id=\"formatted_text_20758\" class=\"paragraph paragraph--formatted-text\">\n<div class=\"paragraph-content\">\n<p>Genethon, the Telethon laboratory, and Hansa Biopharma, a pioneer in enzyme technology for rare immunological diseases, today announced the launch of a phase 2 trial in patients suffering from Crigler-Najjar disease, a rare liver disorder, and presenting with pre-existing neutralising antibodies against AAV vectors.<\/p>\n<p>The trial will evaluate the efficacy and safety of a single intravenous injection of the gene therapy developed by Genethon, after pre-treatment with imlifidase, a unique antibody-cleaving enzyme developed by Hansa.<\/p>\n<p><a href=\"https:\/\/www.afm-telethon.fr\/en\/news\/genethon-and-hansa-biopharma-launch-phase-2-clinical-trial-crigler-najjar-syndrome\">Read more<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The trial will be conducted in patients for whom pre-existing anti-AAV antibodies are currently a limitation to gene therapy treatment. Genethon, the Telethon laboratory, and Hansa Biopharma, a pioneer in enzyme technology for rare immunological diseases, today announced the launch of a phase 2 trial in patients suffering from Crigler-Najjar disease, a rare liver disorder, &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/2024\/12\/03\/genethon-and-hansa-biopharma-launch-a-phase-2-clinical-trial-for-crigler-najjar-syndrome\/\">[Read more]<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-6755","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=6755"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6755\/revisions"}],"predecessor-version":[{"id":6756,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6755\/revisions\/6756"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=6755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/categories?post=6755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/tags?post=6755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}